Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with ipilimumab within its marketing authorisation for untreated advanced unresectable recurrent or metastatic oesophageal cancer.
Please note that following on from information provided to NICE by the company in December 2022, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1629
Project Team
- Project lead
- Michelle Adhemar
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 January 2025 | Discontinued. Please note that following on from information provided to NICE by the company in December 2022, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued |
| 06 December 2022 | Note added to the project documents |
| 05 October 2021 | Suspended. As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712] and Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]. Please note that following on from information received from the company, these appraisals have been combined and will be appraised as one Single Technology Appraisal [ID2712]. The timelines have been revised and the appraisal is now anticipated to begin in mid- January 2022 when we will write to stakeholders about how they can get involved. |
| 16 April 2021 - 17 May 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 14 July 2020 | Note added to the project documents |
| 24 January 2020 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual